Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic
Sign Up to like & getrecommendations! Published in 2023 at "CNS Spectrums"
DOI: 10.1017/s1092852923001645
Abstract: Abstract Introduction Lumateperone (LUMA) is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. An open-label study (Study 303) evaluated the safety and tolerability of LUMA in… read more here.
Keywords: safety; ris pal; previous antipsychotic; stable schizophrenia ... See more keywords
Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
Sign Up to like & getrecommendations! Published in 2017 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s130483
Abstract: Objective The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment. Methods In this 8-week, open-label,… read more here.
Keywords: treatment; patients dissatisfied; previous antipsychotic; treatment satisfaction ... See more keywords